Home > Meetings : Guidelines/Pathways Seminar
Cancer Guidelines and Pathways in the Community Setting. . . A first-ever seminar for physicians, pharmacists, and cancer program executives
On December 7-8, 2011, physicians, pharmacists, and cancer program executives gathered at Fox Chase Cancer Center in Philadelphia for ACCC's first-ever seminar on the changing landscape in oncology payment and strategies for integrating cancer guidelines and pathways into daily practice. Experts and panelists from cancer programs and oncology practices who have begun to utilize cancer management systems reviewed the process by which they selected and implemented their system.
Read more about this meeting:
The Holy Grail of Cost Savings in Oncology?
Better Outcomes, Decreased Costs with Oncology Clinical Pathways
Cancer Management Systems: A New Value Proposition
Michael V. Seiden, MD, PhD, (at center) president of the Fox Chase Cancer Center welcomed meeting attendees--cancer program administrators, oncology pharmacists, and pharmaceutical industry representatives. ACCC President Thomas L. Whittaker, MD, FACP, (left) and ACCC Executive Director Christian Downs, JD, MHA, are also shown.
Understanding how hospital formularies work and how new therapies may be added at cancer programs were topics of a panel discussion. Moderator Ron Schleif, RPh, MBA, Oncology Reimbursement Management, (at left) led panelists Dwight D. Kloth, PharmD, FCCP, BCOP, Fox Chase Cancer Center, and Fuad M. Hammoudeh, FACHE, Indiana University Health, in a discussion about the formulary process from request to purchasing.
A panel of vendors and experts received detailed questions about the value and challenges of clinical pathway/cancer management systems. The bottom line: These systems offer great promise for creating efficiencies and saving money (just how much remains unclear), and possibly improving outcomes. Whether small oncology practices have the numbers, consensus, and leverage with payers to establish evidence-based oncology treatment protocols designed to offer standardized patient assessment and disease management support remains unclear at this time.
Matt Farber, MA, ACCC’s director of provider economics and public policy, moderated discussions on the changing landscape of payment models in community oncology and the role physicians and pharmacists are playing in developing these new models.
ACCC's MyNetwork
Facebook
LinkedIn
Twitter
ACCC Vision Channel